Point-of-care testing: Twenty years' experience

Laboratory Medicine

Volumn 39, Issue 9, 2008, Pages 560-563

  Wagar, Elizabeth A ^a   Yasin, Bushra ^a   Yuan, Shan ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 59849105583     PISSN: 00075027     EISSN: None     Source Type: Journal    
DOI: 10.1309/9R9Y0V68Y3BA0KDN     Document Type: Article

References (27)

1. Ehrmeyer SS, Laessig RH. Point-of-care testing, medical error, and patient safety: A 2007 assessment. Clin Chem Lab Med. 2007;45:726-733.
2. Available at: www.futurelabmed.org/reports/ chapter_ii_-market_profile.pdf. Accessed on: 6-5-2008.
3. Stephen EJ. Developing open standards for connectivity. In Vitro Diagnostics Technology. 1999;5:22-25. Cambridge Consultants. POCT diagnostic market report. Cambridge (UK):2006.
4. Hughes, M. Market trends in point-of-care testing. Point of Care. 2002;1:84-94.
5. Centers for Medicare and Medicaid Services (CMS), Department of Health and Human Services: Clinical Laboratory Improvement Amendments of 1988 (CLIA). Fed Regist. 2003;1047:68 (codified at 42 CFR 493.1299(g), Oct. 1, 2004 ed.
6. Kost GJ, Ehrmeyer SS, Chernow B, et al. The laboratory-clinical interface: Point-of-care testing. Chest. 1999;115:1140-1154, CLSI, POCT4-A2: Point-of-Care In Vitro Diagnostic (IVD) Testing: Approved Guideline, 2nd Edition. 2006.
7. Stephans EJ. Hospital point-of-care survey report (Enterprise Analysis Corp., presented at: Connectivity Industry Consortium Meeting; Oct. 20, 1999, Redwood City, CA.
8. Enterprise Analysis Corp. 2001, POCT Survey.
9. Kost GJ. Connectivity: The millennium challenge for point-of-care testing. Arch Pathol Lab Med. 2000;124:1108-1109.
10. Byrdy PC, Mappes RP, Stephan EJ. Point-of-care connectivity standard: Progress in compliance. Point of care. Journal of Near Patient Testing and Technology. 2003;2:39-48.
11. Cook CB, Moghissi E, Joshi R, et al. Inpatient point-of-care bedside glucose testing: Preliminary data on the use of connectivity informatics to measure hospital glycemic control. Diabetes Technol Ther. 2007;9:493-500.
12. Zaloga GP. Evaluation of bedside testing options for the critical care unit. Chest. 1990;97:S185-S190.
13. Trundle DS, Weizenecker RA. Capillary glucose testing: A cost-saving bedside system. Lab Managem. 1986;24:59-62.
14. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of longterm complications in insulin-dependent diabetes mellitus. N. Engl J Med. 1993;329:977-986.
15. Van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in the critically ill patient. N Engl J Med. 2001;345:1359-1367.
16. Van den Berghe G, Wilmer A, Hermans G, et al. Intensive insulin therapy in the medical ICU. N Engl J Med. 2006;354:449-461.
17. Sadhu AR, Ang AC, Ingram-Drake LA, et al. Economic benefits of intensive insulin therapy in critically ill patients: The TRIUMPH project. Diabetes Care. 2008. In press.
18. Joint Commission Web site. Available at: www.jointcommission.org/ PatientSafety?NationalPatientSafetyGoals/08. Accessed on: 6-16-2008.
19. Cannegieter SC, Rosendaal FR, Wintzen AR, et al. Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med. 1995;333:11-17.
20. Horsti J, Uppa H, Vilpo JA. Poor agreement among prothrombin time international normalized ratio methods: Comparison of seven commercial reagents. Clin Chem. 2005;31:553-560.
21. Poller L, Keown, M, Chauhan N, et al. Reliability of international normalized ratios from two point of care test systems: Comparison with conventional methods. Brit Med J. 2003;327-330.
22. Kaatz SS, White RH, Hill J, et al. Accuracy of laboratory and portable monitor international normalized ratio determinations. Comparison with a criterion standard. Arch Intern Med. 1995;155:1861-1867.
23. WHO guidelines for thromboplastins and plasma used to control oral anticoagulation therapy: Annex 3. WHO Rep Ser. 1999;889:64-93.
24. Winkelman JW, Wybenga DR, Tansijevic JM. The fiscal consequences of central vs. distributed testing of glucose. Clin Chem. 1994;40:1628-1630.
25. Howanitz PJ, Jones BA, Comparative analytical costs of central laboratory glucose and bedside glucose testing: A College of American Pathologists Q-Probes study. Arch Pathol Lab Med. 2004; 238:739-745.
26. FDA-Approved Rapid HIV Antibody Screening Tests - Purchasing Details. Available at: www.cdc.gov/hiv/topics/testing/rapid/rt-purchasing.htm. Accessed on: 7-11-2008.
27. Hortin GL. Does point-of-care testing save money or cost more? Lab Med. 2004;36:465-467.